EU/3/16/1810

About

On 12 January 2017, orphan designation (EU/3/16/1810) was granted by the European Commission to ProMetic Pharma SMT Limited, United Kingdom, for 3-pentylbenzeneacetic acid sodium salt for the treatment of Alström syndrome.

Key facts

Active substance
3-pentylbenzeneacetic acid sodium salt
Medicine name
-
Disease / condition
Treatment of Alström syndrome
Date of decision
12/01/2017
Outcome
Positive
Orphan decision number
EU/3/16/1810

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

ProMetic Pharma SMT Limited
Horizon Park, Barton Road
Comberton
Cambridge CB23 7AJ
United Kingdom
Tel. +44 (0)1223 433 822
E-mail: regaffairsuk@prometic.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating